ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Tenofovir

Also written as “Tenofovir disoproxil fumarate”, “Tenofovir DF” and “tenofovir”.

Its studies are mostly in Hepatitis B, Chronic · HIV Infections · Hepatitis B · Acquired Immunodeficiency Syndrome · Hepatitis C, led by 12 companies.

Drug pageTenofovir: every studyMany companies study it; this page follows only the 53 they lead. All 291 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Mar 23, 200553 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Gilead Sciencesits history only291 open or runningphase 4since Mar 23, 2005Nov 2, 1999none ahead
GlaxoSmithKlineits history only90 open or runningphase 4since May 31, 2002May 31, 2002none ahead
Hoffmann-La Rocheits history only30 open or runningphase 3since Mar 16, 2010Aug 19, 2009none ahead
Laboratorio Elea Phoenixits history only20 open or runningphase 4since Oct 10, 2017Oct 19, 2015none ahead
Novartisits history only20 open or runningphase 4since Dec 7, 2006Dec 7, 2006none ahead
Samjin Pharmaceuticalits history only20 open or runningphase 4since Feb 25, 2022Feb 25, 2022none ahead
Boryung Pharmaceutical10 open or runningphase 1since Sep 29, 2016Sep 29, 2016none ahead
Daewoong Pharmaceuticalits history only10 open or runningphase 4since Mar 27, 2018Mar 27, 2018none ahead
Dong-A STits history only10 open or runningphase 1since Sep 22, 2015Sep 22, 2015none ahead
New Discoveryits history only10 open or runningphase 4since Mar 18, 2018Mar 18, 2018none ahead

Also a collaborator on its studies: C&R Research, Almedis and Bristol-Myers Squibb.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Boryung Pharmaceutical only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jun 9, 2016Named tenofovirINNProposed as its International Nonproprietary Name in WHO's List 115
  2. Sep 29, 2016First study: phase 1 study in HepatitisFirst studyNCT02920931 · 50 enrolled · Korea, Republic of

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

The one study Boryung Pharmaceutical leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02920931Hepatitis · Korea, Republic of1CompletedApr 201650

How it is read

Names in the registry

  • “Tenofovir disoproxil fumarate”, 13 entries
  • “Tenofovir”, 7 entries
  • “Tenofovir DF”, 6 entries
  • “tenofovir”, 5 entries
  • “TDF”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.